The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1419
Nutritional Supplements for Age-Related Macular Degeneration Revisited
The full article is available to subscribers Subscriber Login   
Revised 6/10/14: The last sentence in the Conclusion has been changed.

The results of the Age-Related Eye Disease Study 2 (AREDS2) have now been published.1 The primary purpose of the study was to evaluate the efficacy and safety of the carotenoids lutein and zeaxanthin and the omega-3 polyunsaturated fatty acids (PUFAs) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) in reducing the risk of developing advanced age-related macular degeneration (AMD). A secondary goal was to test the effects of reducing the amount of zinc and eliminating beta carotene from the original AREDS formulation.2 Beta carotene has been shown to increase the risk of lung cancer in smokers and former smokers.3,4

BACKGROUND — The first AREDS trial recruited 3640 patients 55-80 years old who had AMD at various stages. Patients were randomized (double masked) to: (1) antioxidants at doses 5 to 15 ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Nutritional Supplements for Age-Related Macular Degeneration Revisited
Article code: 1419b
 Electronic, downloadable article - $25